Are sunscreens safe?
That’s the question that will be on the minds of many as the Food and Drug Administration releases a second study on the absorption of sunscreens. The reality is that answering the “safe” question is becoming more complicated—and more important as well, given the fact that so many of us use sunscreens as part of our own sun safety efforts, while others (me included) use sunscreen as part of our daily routine.
Despite the questions raised in this study, the FDA concludes:
“These findings do not indicate that individuals should refrain from the use of sunscreen.” (Emphasis mine)
It is a difficult balancing act pitting product safety up against the prevention of some very nasty cancers. It leaves many consumers and experts in the midst of a quandary of what to do and what to recommend.… Continue reading →
The American Cancer Society’s annual report on cancer statistics has been published, and it brings with it more “good news” about the progress against cancer. However, there are also some notable areas of concern that should lead us to reinforce our focus on what we need to do to continue to reduce the burden and suffering from cancer in the United States—and make even more progress.
The good news is that the decline in the rate of deaths from cancer continues to improve: from 1991 (when the cancer death rate in this country was at its peak) until 2017 (the most recent year for which data is available) there was a decline of 29% in the cancer death rate. That translates into 2.9 million fewer deaths from cancer than would have been expected had the rate of cancer deaths not changed from 1991.
And while all most other non-cancer related causes of deaths were increasing or remaining stable, the rate of deaths from cancer declined by a remarkable 2.2% from 2016 to 2017, continuing a long string of declines over many years. This was in fact the largest single-year drop in cancer mortality since rates began falling in the early … Continue reading →
Words have meaning. And when it comes to cancer, especially advanced cancer, there aren’t many words that have more meaning than the word “cure.” Yet it is that very word and concept that is top of mind for some of us these days.
We clinicians are guilty as charged when it comes to reluctance declaring those who have had a remarkable response to treatments for advanced cancer “cured.” Experience has taught us over decades that we have misused the word and overpromised those we cared for. Our patients and loved ones have paid a price for our over optimism. Consequently, our culture has taught us to avoid the word, lest we be shown to have been less-than-truthful when a cancer returns with a vengeance.
And yet our world is changing: we are now seeing long term responses to treatments in diseases where until recently we had little hope of such success.
Recent reports of rapidly declining mortality in melanoma, normal life spans for many people treated for previously fatal diseases like chronic myelogenous leukemia, and the potential for impressive gains in outcomes for people with lung cancer are but a few examples that suggest we are indeed in … Continue reading →
Here is some news about cancer that isn’t widely known and is hiding in plain sight: Deaths from melanoma—a skin cancer that has lethal potential—have declined dramatically over the past several years. And while that fact alone is surprising, so is the reason behind the drop.
Let’s make something clear at the outset: too many people die from melanoma. It is not the most common skin cancer (the American Cancer Society estimates 96,480 people in the United States will be diagnosed with melanoma in 2019, and 7,230 will die from it), but it is much more likely to spread and lead to death than most other much more common forms of skin cancer. And it has too frequently been a fatal disease.
That is now beginning to change, thanks in part to public awareness and earlier diagnosis. However, we can’t ignore what may be the most important factor: much better treatments. In fact, improvement in treatments with targeted drugs and immunotherapies have now begun to have a considerable impact saving lives for those with advanced melanoma.… Continue reading →
The news report in the Jerusalem Post regarding researchers’ claim that they have found a cure for cancer is certain to get our attention. And, it goes without saying, we all share the aspirational hope that they are correct. Unfortunately, we must be aware that this is far from proven as an effective treatment for people with cancer, let alone a cure.… Continue reading →
Good news is always welcome, especially when talking about something as serious as cancer. And there is plenty of welcome information in the American Cancer Society’s release today of our annual report on “Cancer Statistics, 2019” and its accompanying consumer-oriented version of “Cancer Facts & Figures 2019.”
Among the good news in this report: A significant decline in death rates from cancer—especially among some of the most common cancers, significant improvements in early detection and treatment of cancer, and a decrease in the disparities in death rates between African-Americans and whites.
Despite the good news, unfortunately, there are also pieces of the puzzle that have not been solved. And to ignore that information is a disservice to those who struggle with cancer and those who have passed because of this dread disease. The reality is we can—indeed, we must—do better. And that fact is an equally important part of the information contained in this report.… Continue reading →
A recent research report on melanoma from the Centers for Disease Control and Prevention received virtually no notice, yet one of the statistics in that report was—at least for me—stunning, and marked a rare public health win.
People in public health know all too well the gap between educating people about cancer risks and seeing actual results. Skin cancer is no different: We have known for many years that the risk of skin cancer is related to exposure to UV radiation, either from the sun of for indoor tanning.
Yet despite widespread efforts to educate people about this very real cancer risk, we haven’t made much progress reducing its frequency—at least until now.… Continue reading →
Sometimes It’s important to know the news behind the news: the comments and the cautions that don’t get into the article that the public gets to read. It’s the sort of thing that keeps me up at night: trying to convey the reality, while realizing what most people want to hear is the hope.
That’s the problem I have with a story posted on a major news network website yesterday, where I have a brief quotation that failed to capture the thoughts I tried to express at the time of the interview. The reporter had very limited time, and the information I wanted to provide was complicated. Instead of the caution I tried to convey to counter the potential “hype” about chewing gum to find cancer early, the report suggests that this is a test that will be available soon—while failing to inform how complicated it would be to achieve that goal.… Continue reading →
4.9 million—yes, million— people are diagnosed with skin cancer every year in the United States. It costs an estimated $8.1 billion—with a “B— to treat those skin cancers, according to the Centers for Disease Control (CDC).
Do I have your attention? I hope so. The problem is we don’t have enough attention. There is no other way to explain why too many states still allow those under 18 to access tanning beds across this country.
Have we made progress? Yes, but not nearly enough according to a research paper and editorial published today in JAMA Dermatology.
The study, from the CDC, looked at surveys of high school students done every two years between 2009 and 2015. The researchers found that overall the frequency of tanning bed use in the previous year declined from 15.6% of all high school students in 2009 to 7.3% of all students in 2015.
That’s progress. However, when they took a closer look at different groups of students they found that among non-Hispanic white female students the numbers using a tanning bed the previous year dropped from 37.4% to 15.2%.
Sound good? Maybe—until you look at the percentages for those 17 and older: in … Continue reading →
Cancer drugs—especially the new targeted and immunotherapies—are very, very expensive.
No doubt about that, and there is also no lack of effort trying to cast blame on who bears responsibility for those costs. There is even a recent article in the British Medical Journal that analyzes the size of the vials those drugs come in and suggests for some companies at least that may be a strategy to increase costs even further. What most experts can agree on is that this is a complicated problem for which there are no easy solutions.
I recently wrote a short commentary on the issue which appeared in Healio’s “HemOnc Today.” Although not exhaustive in terms of analyzing the issue, it does point out that we need to find a balance that continues to provide the incentive to innovate and bring new treatments to the care of cancer patients, while maintaining some degree of restraint given the reality that these costs simply cannot continue to increase without limit.… Continue reading →